OGB23502

OGB23502 is a multi-target immuno-oncology candidate being developed by ONEGENE. It is engineered using the company's proprietary UniStac (Universal Stabilized Trimer) platform, which allows for the creation of multi-specific biologics by fusing functional domains to a stabilized trimeric scaffold. OGB23502 is designed to simultaneously target Programmed cell death protein 1 (PD-1) and Vascular endothelial growth factor (VEGF), along with a third undisclosed target. This triple-targeting approach aims to combine immune checkpoint inhibition with anti-angiogenesis and an additional undisclosed mechanism to enhance anti-tumor immune responses and overcome resistance in various cancers. As of the latest pipeline information, OGB23502 is in the lead discovery stage of development.